Pinakin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-01-2025
- Paid Up Capital ₹ 0.10 M
as on 11-01-2025
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 46.23%
(FY 2022)
- Profit -1453.42%
(FY 2022)
- Ebitda -141.70%
(FY 2022)
- Net Worth -7.37%
(FY 2022)
- Total Assets 2.74%
(FY 2022)
About Pinakin Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ankit Gupta, Shashi Gupta, and Jyoti Gupta serve as directors at the Company.
- CIN/LLPIN
U24230GJ2014PTC078648
- Company No.
078648
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Feb 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Pinakin Pharmaceuticals Private Limited offer?
Pinakin Pharmaceuticals Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Herbal Soaps, Neem Soap, Physiotherapy & Rehab Aids, Rehabilitation Equipment, Infusion Syringes & Supplies, Medical Tubes, Bath Soaps, Ketoconazole Soap, Bandages & Dressing Disposables.
Who are the key members and board of directors at Pinakin Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankit Gupta  | Director | 10-Feb-2014 | Current |
| Shashi Gupta | Director | 13-Nov-2014 | Current |
| Jyoti Gupta | Director | 19-Jul-2021 | Current |
Financial Performance of Pinakin Pharmaceuticals.
Pinakin Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 46.23% increase. The company also saw a substantial fall in profitability, with a 1453.42% decrease in profit. The company's net worth dipped by a decrease of 7.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pinakin Pharmaceuticals?
In 2017, Pinakin Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pinakin Pharmaceuticals?
Unlock and access historical data on people associated with Pinakin Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pinakin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pinakin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
